Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.
Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.
Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.
Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).
Marco ToniPartner Attorney at law
Marco Toni, attorney at law, is a partner in our Zurich office. He focuses on domestic and international M&A transactions, private equity, corporate governance and general corporate, stock exchange and capital markets laws.T: +41 43 434 67 15 M: +41 79 557 62 15 E: email@example.com
Rebecca KühneAssociate Swiss certified tax expert
Rebecca Kühne, Swiss certified tax expert, is an associate in our Zurich office. She also focuses on Swiss VAT matters and supports clients in the context of non-contentious procedures.T: +41 43 434 67 34 M: +41 79 814 06 19 E: firstname.lastname@example.org